Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

被引：0
|
作者：
Nicola J. Lawrence
Howard Chan
Guy Toner
Martin R. Stockler
Andrew Martin
Sonia Yip
Nicole Wong
Annie Yeung
Danish Mazhar
Farzana Pashankar
Lindsay Frazier
Ray McDermott
Roderick Walker
Hsiang Tan
Ian D. Davis
Peter Grimison
机构：
[1] Australian and New Zealand Urogenital and Prostate Cancer Trials Group,Peter MacCallum Cancer Centre
[2] NHMRC Clinical Trials Centre,Concord Cancer Centre
[3] University of Melbourne,Sydney Catalyst Translational Cancer Research Centre
[4] Chris O’Brien Lifehouse,undefined
[5] Concord Repatriation General Hospital,undefined
[6] University of Sydney,undefined
[7] Cambridge University Hospitals NHS Foundation Trust,undefined
[8] Yale University School of Medicine,undefined
[9] Dana-Farber Cancer Institute and Boston Children’s Hospital,undefined
[10] Cancer Trials Ireland,undefined
[11] Lady Cilento Children’s Hospital,undefined
[12] Princess Alexandra Hospital,undefined
[13] Royal Adelaide Hospital,undefined
[14] Monash University Eastern Health Clinical School,undefined
来源：
BMC Cancer | / 18卷
关键词：
Germ cell tumours; Phase 3 trial; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 26 条
  • [21] Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumours (NSGCT): Final results of phase II trial
    Tryakin
    Fedyanin, M.
    Segeev, Y.
    Bulanov, A.
    Matveev, V. B.
    Volkova, M.
    Klimov, A.
    Fainstein, I.
    Akhmedov, B.
    Menshikova, S.
    Zakharova, T.
    Garin, A. M.
    Chekini, D.
    Chekini, A.
    Sekhina, O.
    Tjulandin, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): Efficacy results of phase II trial
    Tryakin, Alexey
    Fedyanin, Mikhail
    Sergeev, Urii
    Bulanov, Anatoly
    Ahmedov, Bahrom
    Zakharova, Tatiana
    Mitin, Andrey
    Fainstein, Igor
    Garin, Avgust
    Tjulandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).
    Feldman, Darren R.
    Hu, James S.
    Patil, Sujata
    Reuter, Victor E.
    Srinivas, Sandy
    Stadler, Walter Michael
    Costello, Brian Addis
    Milowsky, Matthew I.
    Appleman, Leonard Joseph
    Dorff, Tanya B.
    Bromberg, Maria
    Joseph, Gabriella
    Funt, Samuel Aaron
    Bajorin, Dean F.
    Bosl, George J.
    Quinn, David I.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
    Feldman, Darren R.
    Hu, James
    Srinivas, Sandy
    Stadler, Walter Michael
    Costello, Brian Addis
    Appleman, Leonard Joseph
    Milowsky, Matthew I.
    Patil, Sujata
    Bromberg, Maria
    Nolan, Patrick
    Dorff, Tanya B.
    Reuter, Victor E.
    Al-Ahmadie, Hikmat
    Funt, Samuel
    Bajorin, Dean F.
    Bosl, George J.
    Quinn, David I.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
    Gronchi, Alessandro
    Ferrari, Stefano
    Quagliuolo, Vittorio
    Martin-Broto, J.
    Lopez Pousa, Antonio
    Grignani, Giovanni
    Basso, Umberto
    Blay, Jean-Yves
    Tendero, Oscar
    Diaz Beveridge, Robert
    Ferraresi, Virginia
    Lugowska, Iwona
    Merlo, Domenico Franco
    Fontana, Valeria
    Marchesi, Emanuela
    Donati, Davide Maria
    Palassini, Elena
    Palmerini, Emanuela
    De Sanctis, Rita
    Morosi, Carlo
    Stacchiotti, Silvia
    Bague, Silvia
    Coindre, Jean Michelle
    Dei Tos, Angelo Paolo
    Picci, Piero
    Bruzzi, Paolo
    Casali, Paolo Giovanni
    LANCET ONCOLOGY, 2017, 18 (06): : 812 - 822
  • [26] Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial (vol 18, pg 812, 2017)
    Gronchi, A.
    Ferrari, S.
    Quagliuolo, V
    LANCET ONCOLOGY, 2017, 18 (06): : E301 - E301
123